文献速递肝病

慢性阿片类药物使用与肝硬化患者肠道菌群改变相关并预测再入院

Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2016-11-20

研究纳入200例肝硬化住院患者前瞻性随访6个月,另比较72例慢性阿片使用与72例年龄/MELD/既往HE匹配的对照。慢性阿片使用与全因再入院(69% vs 48%,P=0.008)及内毒素血症、菌群失调相关,但与HE相关再入院无显著差异(30% vs 41%,P=0.30)。

要点

  • 慢性阿片使用与肝硬化患者全因再入院率升高相关(69% vs 48%,P=0.008)。
  • 阿片使用与HE相关再入院无显著差异(30% vs 41%,P=0.30)。
  • 阿片使用组内毒素血症和IL-6升高,菌群失调以自体菌群及拟杆菌科相对丰度降低为特征。

核心结论

  • 肝硬化患者慢性阿片使用与内毒素血症增加、菌群失调及全因再入院增多相关。

研究设计与样本

  • 队列1为200例肝硬化住院患者(使用/不使用阿片),前瞻性随访住院期间及出院后6个月,比较再入院。
  • 队列2为72例慢性阿片使用的肝硬化患者,与72例年龄/MELD/既往HE匹配的非阿片使用者比较粪便菌群组成、预测功能、内毒素血症及全身炎症。

主要发现

  • 队列1中,144例6个月时存活患者中82例再入院;阿片使用者全因再入院显著更高(69% vs 48%,P=0.008),HE相关再入院无显著差异(30% vs 41%,P=0.30)。
  • 回归分析中,阿片治疗和女性性别可独立于MELD评分和既往HE预测再入院。
  • 队列2中阿片组存在显著菌群失调,尤其HE+阿片患者自体菌群和拟杆菌科相对丰度降低。
  • PiCRUST显示阿片使用者芳香族氨基酸和内毒素产生最高。
  • 阿片使用者内毒素血症和IL-6更高,但IL-17无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Opioid use is epidemic in cirrhosis, which could precipitate hepatic encephalopathy (HE) potentially through gut dysbiosis and inflammation. AIM: To define the effect of opioids on readmissions and on gut microbiota composition and functionality. METHODS: Cohort 1 had 200 cirrhotic in-patients (with/without opioid use) followed prospectively through the index hospitalisation and 6 months post discharge. Readmissions (HE-related/unrelated) were compared between patients discharged on opioids compared to the rest, including using a multi-variable analysis. Cohort 2 consisted of 72 cirrhotics on chronic opioids who were age/model for end-stage liver disease (MELD) and prior HE-balanced with 72 cirrhotics not on opioids. Stool microbiota composition (multi-tagged sequencing), predicted functionality (PiCRUST), endotoxemia and systemic inflammation (IL-6, IL-17) were compared. RESULTS: Cohort 1: Chronic opioid use was statistically similar between those admitted with/without HE, and was judged to be an HE precipitant in <5% of cases during the index hospitalisation. Of the 144 patients alive at 6 months, 82 were readmitted. The opioid users had a significantly higher all cause (69% vs. 48%, P = 0.008), but not HE-related readmissions (30% vs. 41%, P = 0.30). On regression, opioid therapy and female gender were predictive of readmission independent of MELD score and previous HE. Cohort 2: Significant dysbiosis was noted in the opioid cohort, especially in HE+opioid patients with lower autochthonous taxa and Bacteroidaceae relative abundance. PiCRUST showed highest aromatic amino acid and endotoxin production in opioid users. Opioid users also had higher endotoxemia and IL-6 but not IL-17. CONCLUSION: Chronic opioid use in cirrhosis is associated with increased endotoxemia, dysbiosis and all-cause readmissions.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Acharya C, Betrapally NS, Gillevet PM, et al. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther. 2016. PMID: 27868217. doi:10.1111/apt.13858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。